top of page

About NCPC

The Northwestern Cancer Prevention Consortium (NCPC) was initially funded in 2003 as a contract with the National Cancer Institute, Division of Cancer Prevention (NCI DCP), and was led by Raymond Bergan, MD. In 2015, Seema Khan, MD took over as the Consortium's Principal Investigator when Dr. Bergan moved to another institution. 

In 2018, NCI DCP changed the funding structure from a contract to a highly competitive cooperative group grant mechanism, called the Cancer Prevention Clinical Trials Network (CP-CTNet). NCPC successfully competed and renewed as one of five Consortium Lead Academic Organizations

For cancer prevention researchers, the NCI DCP CP-CTNet offers unique advantages over other funding mechanisms for the conduct of early-phase trials. The applicant pool is restricted, so the success rate is far higher than through other mechanisms. Between 2012 and 2017, 59% of NCPC's proposals were funded, compared to only 12% for unsolicited R01 proposal submissions. Additionally, the final trial design benefits from discussions with a core group of dedicated cancer prevention researchers within the NCPC and at DCP, and the NCPC provides connections within a network of research-capable institutions for multisite recruitment. The regulatory burden is largely assumed by the NCPC Core Administrative Team. For junior investigators, this is a particularly supportive environment, and provides access to a group of clinical scientists and trial administrators who are highly experienced in the cancer prevention setting.

​The NCPC is a part of the Robert H. Lurie Comprehensive Cancer Center (RHLCC). The RHLCC is a national leader in cancer research and resources, supporting care for a broad range of cancer types, thanks to a distinguished and dedicated faculty and staff, a world-class teaching program and a commitment to making ongoing advances in medical, surgical, radiation and interventional oncology.


Based on guidance from NCI DCP, the NCPC supports cancer and immunoprevention trials that:

  • Study people in high-risk categories for certain types of cancer (colorectal adenoma, BRCA+, liver cirrhosis).

  • Enroll between 15 and 150 participants.

  • Have a treatment phase that lasts between 1 and 6 months.

  • Target multiple chronic disease.

  • Explore localized therapies, alternative dosing regimens, and innovative trial designs.

  • Use innovative study agents (molecularly targeted agents and repurposing drugs).

Pending, recruiting, and recently concluded trials include:​

bottom of page